Ngwa ihe ọchị oke bekee ndị na-emepụta ihe, ndị na-ebubata ihe, ụlọ ọrụ mmepụta ihe
Site na kredit azụmaahịa dị mma, ọmarịcha ọrụ ahịa na ụlọ nrụpụta ọgbara ọhụrụ, anyị enwetala aha ọma n'etiti ndị ahịa anyị gburugburu ụwa maka oke bekee-aqueous-humor-kit,Ngwa mmiri Cerebrospinal enwe, cyp2c9 igbe, ihe CD19+ mmadụ, akpa PBMC ngwa. Anyị ga-agba mbọ idowe aha ọma anyị dị ka ndị na-ebubata ngwaahịa kacha mma n'ụwa. Ọ bụrụ na ị nwere ajụjụ ọ bụla ma ọ bụ kwuo, biko kpọtụrụ anyị n'efu. Iji nweta ntụkwasị obi nke ndị ahịa, Isi mmalite ewepụtala ahịa siri ike na mgbe - otu ndị na-ere ahịa iji nye ngwaahịa na ọrụ kacha mma. Isi mmalite kachasị mma na-agbaso echiche nke "Too na ndị ahịa" na nkà ihe ọmụma nke "Customer-gbakwasara" iji nweta nkwado nke ntụkwasị obi na uru. Ebe kacha mma ga-adị njikere mgbe niile ịkwado gị. Ka anyị tolite ọnụ!ngwa microsomes imeju mmadụ, ugt1a6 ngwa, Ngwa nke anụ ahụ prostate, Ngwa nke anụ ahụ ovary.
IPHASE, dị ka onye ndu na ndu reagents maka in vitro nnyocha nke ọhụrụ ọgwụ, na-aga n'ihu na-ewebata elu - ọgwụgwụ nnyocha reagents n'ọtụtụ ubi na ụdị dabere na afọ nke nnyocha na mmepe ahụmahụ.
Ụdị nyocha PDC in vitro ADME PDC na-eburu n'uche njirimara nke ma nnukwu ma obere ụmụ irighiri ihe. Ya mere, in vitro ADME nyocha na ya kwesịrị iburu n'uche peptides homing, njikọ
Okwu Mmalite nke Tritosomes● Nkọwa na mkpa Tritosomes bụ ihe owuwu subcellular pụrụ iche na-etinye aka na usoro cellular dị iche iche, karịsịa na nhazi nke ụzọ metabolic.
N'oge na-adịbeghị anya, IPHASE, yana njikọ Perelman School of Medicine na University of Pennsylvania, dere otu isiokwu na akwụkwọ akụkọ Antibody Therapeutics (IF=4.56) nke akpọrọ "Development of a
● Mmalite nke nnwale chromosome aberration Nnwale chromosome aberration bụ ngwa dị mkpa na nyocha mkpụrụ ndụ ihe nketa na nyocha ụlọ ọgwụ. Emebere ule ndị a iji chọpụta na mara nhazi
Antibody - Drug Conjugate (ADC) bụ ụdị ọgwụ biotechnology ọhụrụ nke na-ejikọ obere ogige ọgwụgwọ molecule na-ezubere iche mgbochi mgbochi / mgbochi mgbochi site na njikọ.